You are here

Current Projects

 
  
 
Looking for a specific type of study? Finding the right fit is simple:
 1. Select your criteria below
 2. Press submit to view your results
 
  

The following projects are currently open and enrolling volunteers. These studies were evaluated and approved by the research team at Dr. Susan Love Research Foundation and members of our external Scientific Advisory Committee, comprised of researchers, clinicians, and advocates.

If you would like to learn about the studies we recruited for in the past, please click here.

  
Researcher: Seema Khan, MD, Northwestern University, Chicago, IL, Joseph Michael Guenther, MD, St. Elizabeth HealthCare, Edgewood, KY, Amy Degnim, MD, Mayo Clinic, Rochester, MN, Melissa Pilewskie, MD, Memorial Sloan Kettering Cancer Center, New York, NY, E. Shelley Hwang, MD, Duke University, Durham, NC, Stephen Grobmyer, MD, Cleveland Clinic, Cleveland, OH
Broadcast date: February 16, 2018

The purpose of this study is to compare the effects of a tamoxifen pill to tamoxifen (4-OHT) gel on breast cells in women with ER+ DCIS. This study will investigate what effects each treatment has on the DCIS and what side effects each treatment may cause. Prior studies show that the topical gel stays mainly in the breast itself with very little getting into the blood. The eventual goal is to provide women with DCIS with an alternative to oral tamoxifen treatment.

Researcher: Laura Esserman, MD, MBA, University of California, San Francisco, CA and her partners from the Athena Breast Health Network (a collaboration across the five University of California Medical Centers and Sanford Health)
Broadcast date: February 16, 2018

Women receive mixed messages about what type of breast cancer screening they should have and how often they should have mammograms. The WISDOM Study compares the routine, annual mammogram schedule to a personalized screening schedule based on a woman’s individual risk factors. The goal of the study is to determine the best way to use mammograms to improve breast cancer screening while reducing the number of call backs, false alarms, and biopsies for women who do not have breast cancer.

Researcher: Tonia Poteat, PhD, and Lorraine T. Dean, ScD of Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Broadcast date: January 12, 2018

The purpose of this study is to learn about the best ways to improve access to breast cancer care and treatment for members of the Black LGBQ-SGL community. The research team will enroll up to 30 participants for an in-depth phone interview about identities and healthcare experiences.  

Researcher: Alexandra Zimmer, M.D., at the National Cancer Institute, Bethesda, MD
Broadcast date: September 19, 2017

The purpose of this study is to investigate whether using Temodar and Kadcyla together decreases the chance of patients with HER2+ metastatic breast cancer developing new brain metastases. Approximately 18 participants will take part in this study. Participants enrolled in this trial may be eligible to receive compensation for their travel expenses.

Researcher: Carolyn Westhoff, MD, Columbia University, New York, NY
Broadcast date: August 9, 2017

Researchers at Columbia University need healthy women in the greater New York City area between the ages of 18 and 39 to participate in a study investigating the effects of two medications on breast cell proliferation. The new pill being studied contains Ulipristal Acetate, or UPA. UPA is a selective progesterone-receptor modulator, or SPRM. Like tamoxifen (a selective estrogen receptor modulator, or SERM), UPA interacts with female hormones that affect the breast. Previous studies show that progesterone increases breast cell growth, and UPA may block this increase. The control medication in this study is a low-dose birth control pill that has been used in the U.S. for over 30 years. The research team wants to see if the UPA pill has a different effect on breast cells than currently used low-dose contraceptive pills. Because SPRM’s hormonal interference can block ovulation, UPA is also a potential contraceptive. This research is the first step in learning if an UPA contraceptive could decrease the long-term risk of breast cancer.

The purpose of this phase I clinical trial is to learn how two different medications affect the breast: an estrogen-free selective progesterone-receptor modulator called UPA vs. a low-dose oral contraceptive pill. This study completed recruitment for the low-dose oral contraceptive group. Now, the research team is looking for participants to enroll in the UPA group.

Researcher: Thomas Mack, MD, MPH, University of Southern California, Los Angeles
Broadcast date: July 12, 2017

This study aims to identify non-genetic factors that cause only one twin in a pair to get breast cancer. This information could help researchers identify ways to help prevent breast cancer from occurring.

Researcher: David Spiegel, MD, Amit Etkin, MD, PhD, James Gross, PhD, and Allison Kurian, MD, MSc, Stanford University School of Medicine. The study is funded by the National Cancer Institute.
Broadcast date: June 7, 2017

The goal of this study is to better understand what women are thinking about and feeling as they decide on their cancer treatments. The results of this study may help researchers develop new interventions that may better assist women newly diagnosed with breast cancer with their treatment decisions.

Researcher: Patricia A. Ganz, MD, Julienne Bower, PhD, and Catherine Crespi, PhD, at University of California, Los Angeles; Ann Partridge, MD, MPH and Hadine Jaffe, MD, MSc at Dana-Farber Cancer Institute; and Antonio Wolff, MD, Katherine Smith, PhD, and Elissa Bantug, MHS, at Johns Hopkins University
Broadcast date: May 3, 2017

The purpose of this study is to see how well two different types of group programs—mindfulness-meditation classes and survivorship education classes—meet the needs of young survivors. Up to 360 women will take part in this study. Three institutions are collaborating on this project: University of California, Los Angeles, Dana-Farber Cancer Institute, and Johns Hopkins University

Researcher: Christine Miaskowski, PhD, RN, University of California, San Francisco
Broadcast date: April 25, 2017

This study is designed to identify both signs and symptoms of breast cancer-related lymphedema and genetic factors that predict whether patients are at increased risk for developing lymphedema. The researchers intend to use the results to develop and test new approaches to prevent or reduce the risk of lymphedema developing following breast cancer treatment.

Researcher: Steven Narod, MD, Women's College Research Institute, Toronto, Ontario, Canada
Broadcast date: March 15, 2017

Genetic and non-genetic factors are believed to influence whether a woman with a BRCA1, BRCA2, and/or PALB2 mutation goes on to develop breast and/or ovarian cancer. The study is trying to identify which hormonal, reproductive, and lifestyle factors may increase cancer risk in this high-risk group.

Pages